SCOPUS 정보 검색 플랫폼

BMC Medicine

Volumn 12, Issue 1, 2014, Pages

Advances in treating HER2-positive breast cancer: An interview with Sunil Verma

(1) Verma, Sunil a

a SUNNYBROOK RESEARCH INSTITUTE (Canada)

Author keywords

Breast cancer; HER2; Oncology

Indexed keywords

ANTIBODY CONJUGATE; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EVEROLIMUS; LAPATINIB; NERATINIB; PERTUZUMAB; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SURGERY; CANCER THERAPY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; GENE IDENTIFICATION; HUMAN; INTERVIEW; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; OVERALL SURVIVAL; PHYSICIAN; QUALITY OF LIFE; RECURRENCE RISK; TERMINAL CARE; ART; BREAST NEOPLASMS; FEMALE; GENETICS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; RECEPTOR, ERBB-2;

EID: 84905815290 PISSN: None EISSN: 17417015 Source Type: Journal
DOI: 10.1186/s12916-014-0129-y Document Type: Article

Times cited : (2)

References (6)

1
- 37049183697
- Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
- 3798106
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
- (1987) Science , vol.235 , pp. 177-182
- Slamon, D.J.¹ Clark, G.M.² Wong, S.G.³ Levin, W.J.⁴ Ullrich, A.⁵ McGuire, W.L.⁶

2
- 0035869407
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
- 11248153
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792. 10.1056/NEJM200103153441101, 11248153.
- (2001) N Engl J Med , vol.344 , pp. 783-792
- Slamon, D.J.¹ Leyland-Jones, B.² Shak, S.³ Fuchs, H.⁴ Paton, V.⁵ Bajamonde, A.⁶ Fleming, T.⁷ Eiermann, W.⁸ Wolter, J.⁹ Pegram, M.¹⁰ Baselga, J.¹¹ Norton, L.¹²

3
- 26844503270
- Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
- 16236737
- Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, La´ng I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ru¨schoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD. Herceptin Adjuvant (HERA) Trial Study Team: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672. 10.1056/NEJMoa052306, 16236737.
- (2005) N Engl J Med , vol.353 , pp. 1659-1672
- Piccart-Gebhart, M.J.¹ Procter, M.² Leyland-Jones, B.³ Goldhirsch, A.⁴ Untch, M.⁵ Smith, I.⁶ Gianni, L.⁷ Baselga, J.⁸ Bell, R.⁹ Jackisch, C.¹⁰ Cameron, D.¹¹ Dowsett, M.¹² Barrios, C.H.¹³ Steger, G.¹⁴ Huang, C.S.¹⁵ Andersson, M.¹⁶ Inbar, M.¹⁷ Lichinitser, M.¹⁸ La´ng, I.¹⁹ Nitz, U.²⁰ more..

4
- 33845886440
- Lapatinib plus capecitabine for HER2-positive advanced breast cancer
- 17192538
- Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743. 10.1056/NEJMoa064320, 17192538.
- (2006) N Engl J Med , vol.355 , pp. 2733-2743
- Geyer, C.E.¹ Forster, J.² Lindquist, D.³ Chan, S.⁴ Romieu, C.G.⁵ Pienkowski, T.⁶ Jagiello-Gruszfeld, A.⁷ Crown, J.⁸ Chan, A.⁹ Kaufman, B.¹⁰ Skarlos, D.¹¹ Campone, M.¹² Davidson, N.¹³ Berger, M.¹⁴ Oliva, C.¹⁵ Rubin, S.D.¹⁶ Stein, S.¹⁷ Cameron, D.¹⁸

5
- 84862914692
- Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer
- Baselga J, Corte´s J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2006, 366:109-119. 10.1056/NEJMoa1113216.
- (2006) N Engl J Med , vol.366 , pp. 109-119
- Baselga, J.¹ Corte´s, J.² Kim, S.B.³ Im, S.A.⁴ Hegg, R.⁵ Im, Y.H.⁶ Roman, L.⁷ Pedrini, J.L.⁸ Pienkowski, T.⁹ Knott, A.¹⁰ Clark, E.¹¹ Benyunes, M.C.¹² Ross, G.¹³ Swain, S.M.¹⁴

6
- 84868520609
- Trastuzumab emtansine for HER2-positive advanced breast cancer
- Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Die´ras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 368:2442. http://www.nejm.org/doi/full/10.1056/NEJMoa1209124., http://www.nejm.org/doi/full/10.1056/NEJMoa1209124
- (2012) N Engl J Med , vol.368 , pp. 2442
- Verma, S.¹ Miles, D.² Gianni, L.³ Krop, I.E.⁴ Welslau, M.⁵ Baselga, J.⁶ Pegram, M.⁷ Oh, D.Y.⁸ Die´ras, V.⁹ Guardino, E.¹⁰ Fang, L.¹¹ Lu, M.W.¹² Olsen, S.¹³ Blackwell, K.¹⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.